Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Helyezés a részvények között #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Részvényárfolyam
$62.26
Utolsó szinkronizálás: 2026-09-22
Piaci kapitalizáció
$127.18B
Változás (1 nap)
-0.78%
Változás (1 év)
38.63%
Ország
US
Kereskedés Bristol-Myers Squibb Company (BMY)

Kategória

Bristol-Myers Squibb Company (BMY) részvényárfolyamának története
Legmagasabb napi záróár: $64.51 ekkor: 2026-09-01

Legalacsonyabb napi záróár: $2.11 ekkor: 1968-01-01
Bristol-Myers Squibb Company részvényárfolyamának története 1968 és 2026 között
Éves részvényárfolyam teljesítmény
Év Teljesítmény
2026 (TTM) 6.53%
2025 -8.39%
2024 12.87%
2023 -32.99%
2022 27.36%
2021 -3.05%
2020 -0.97%
2019 20.53%
2018 -16.81%
2017 7.57%
2016 -16.13%
2015 15.50%
2014 14.61%
2013 59.12%
2012 -4.31%
2011 29.95%
2010 2.97%
2009 15.52%
2008 -22.11%
2007 10.50%
2006 15.64%
2005 -10.44%
2004 -8.12%
2003 7.53%
2002 -52.00%
2001 -20.96%
2000 4.53%
1999 5.13%
1998 33.69%
1997 69.70%
1996 31.38%
1995 44.76%
1994 -0.59%
1993 -15.27%
1992 -14.14%
1991 21.52%
1990 18.58%
1989 23.86%
1988 8.22%
1987 2.55%
1986 24.30%
1985 32.14%
1984 17.78%
1983 23.49%
1982 25.84%
1981 17.29%
1980 25.20%
1979 9.77%
1978 2.15%
1977 0.80%
1976 -5.61%
1975 44.79%
1974 -0.16%
1973 -28.65%
1972 12.02%
1971 -5.18%
1970 -11.28%
1969 0.88%
1968 0.00%
Hasonló cégek vagy versenytársak részvényárai
Vállalat Részvényár Változás 1év% Ország
$1.17K 57.15%
US
$269.55 52.65%
US
$265.85 19.42%
US
$487.45 38.85%
CH
$151.02 88.87%
US